Breaking News

Gilead Licenses Generic Sovaldi

India-based generic manufacturers to expand access to Hep C drugs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences, Inc. has signed non-exclusive licensing agreements with seven India-based generic manufacturers to expand access to its chronic hepatitis C medicines in developing countries. Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. will be able to manufacture sofosbuvir (brand name Sovaldi) and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters